401
Participants
Start Date
August 31, 2002
Primary Completion Date
December 31, 2004
Study Completion Date
November 30, 2005
peginterferon alfa-2a
Ribavirin
New York-Presbyterian Medical Center, New York
University of Maryland School of Medicine, Baltimore
University of North Carolina, Chapel Hill
University of Miami School of Medicine, Miami
University of Michigan Medical Center, Ann Arbor
Rush University, Chicago
University of California, San Francisco, San Francisco
Beth Israel Deaconess Medical Center, Boston
National Institute on Minority Health and Health Disparities (NIMHD)
NIH
National Cancer Institute (NCI)
NIH
National Center for Advancing Translational Sciences (NCATS)
NIH
Hoffmann-La Roche
INDUSTRY
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH